FDA Approves Ribociclib with an Aromatase Inhibitor and Ribociclib and Letrozole Co-pack for Early High-Risk Breast Cancer By Ogkologos - October 28, 2024 329 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy of ribociclib with a non-steroidal aromatase inhibitor is based on the results from the NATALEE study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Indications for Ibrutinib ESMO Highlights the Importance of Prioritising the Fight Against Cancer in Its Response to the Public Consultation on the EU4Health 2026 Work Programme ESMO Urges EU Policymakers to Protect the Wellbeing of the Oncology Workforce MOST POPULAR FDA Grants Accelerated Approval to Tisotumab Vedotin-tftv for Recurrent or Metastatic... September 23, 2021 Community Comes Together To Give Terminally Ill Father One Last Christmas... October 18, 2021 Longer Follow-Up Continues to Support First-Line Pembrolizumab Plus Chemotherapy in Metastatic... March 25, 2021 Nanoparticle Trains Immune Cells to Attack Cancer December 4, 2020 Load more HOT NEWS Immunotherapy Drugs Expand Treatment Options for Advanced Lung Cancer Feeling the pull: Using magnetic drug targeting to improve chemotherapy in... Understanding Genomic Correlates of Response and Acquired Resistance to FGFR Inhibitors Apalutamide Plus ADT Demonstrates a Rapid, Deep, and Durable PSA Decline...
